Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Drugs and Chemicals
2.3. Experimental Design
- Group I (Control group)—each rat received saline as a vehicle (p.o.) for 25 days.
- Group II (Cisplatin control)—received cisplatin (3 mg/kg body weight/day, i.p.).
- Group III (Test group)—animals were treated with cisplatin+ daily treatment of hisutidin orally (by gavage) with the dosage of 10 mg/kg.
- Group IV (Per se group)—received daily treatment of hirsutidin orally (by gavage) with a 10 mg/kg dose.
2.4. Biochemical Parameters
2.4.1. Kidney Tissue Homogenate and Preparation of Biological Samples
2.4.2. Estimation of Uric Acid, Urea, Creatinine, BUN, and Cholesterol
2.4.3. Estimation of Biomarkers of Oxidative Stress
2.4.4. Estimation of Inflammatory Markers
2.4.5. Estimation of Histopathological Investigations
2.5. Statistical Analysis
3. Results
3.1. Effects of Hirsutidinon Uric Acid, Urea, Creatinine, Urine Volume, BUN, and Cholesterol
3.2. Effects of Hrisutidin on Inflammatory Markers
3.3. Effects of Hirsutidin on Histopathological Investigations
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Wu, H.; Huang, J. Drug-induced nephrotoxicity: Pathogenic mechanisms, biomarkers, and prevention strategies. Curr. Drug Metab. 2018, 19, 559–567. [Google Scholar] [CrossRef]
- Mohamed, H.Z.; Shenouda, M.B. Amelioration of renal cortex histological alterations by aqueous garlic extract in gentamicin induced renal toxicity in albino rats: A histological and immunohistochemical study. Alex. J. Med. 2021, 57, 28–37. [Google Scholar] [CrossRef]
- Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 2007, 334, 115–124. [Google Scholar] [CrossRef]
- Aldossary, S.A. Review on pharmacology of cisplatin: Clinical use, toxicity and mechanism of resistance of cisplatin. Biomed. Pharmacol. J. 2019, 12, 7–15. [Google Scholar] [CrossRef]
- Homan, K.A.; Kolesky, D.B.; Skylar-Scott, M.A.; Herrmann, J.; Obuobi, H.; Moisan, A.; Lewis, J.A. Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Sci. Rep. 2016, 6, 34845. [Google Scholar] [CrossRef]
- Chen, N.; Chen, X.; Ding, X.; Teng, J. Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure. Hepatol. Int. 2018, 12, 262–268. [Google Scholar] [CrossRef]
- Gilani, S.J.; Bin-Jumah, M.N.; Al-Abbasi, F.A.; Nadeem, M.S.; Alzarea, S.I.; Ahmed, M.M.; Sayyed, N.; Kazmi, I. Rosinidin Protects against Cisplatin-Induced Nephrotoxicity via Subsiding Proinflammatory and Oxidative Stress Biomarkers in Rats. Int. J. Environ. Res. Public Health 2022, 19, 9719. [Google Scholar] [CrossRef]
- Zhou, J.; Yu, X.; Su, T.; Wang, S.; Yang, L. Critically ill, tubular injury, delayed early recovery: Characteristics of acute kidney disease with renal oxalosis. Ren. Fail. 2021, 43, 425–432. [Google Scholar] [CrossRef]
- Ghosh, S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019, 88, 102925. [Google Scholar] [CrossRef]
- Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378. [Google Scholar] [CrossRef]
- Travis, L.B.; Holowaty, E.J.; Bergfeldt, K.; Lynch, C.F.; Kohler, B.A.; Wiklund, T.; Curtis, R.E.; Hall, P.; Andersson, M.; Pukkala, E. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med. 1999, 340, 351–357. [Google Scholar] [CrossRef]
- Jamieson, E.R.; Lippard, S.J. Structure, recognition, and processing of cisplatin− DNA adducts. Chem. Rev. 1999, 99, 2467–2498. [Google Scholar] [CrossRef]
- Oun, R.; Moussa, Y.E.; Wheate, N.J. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans. 2018, 47, 6645–6653. [Google Scholar] [CrossRef]
- Santabarbara, G.; Maione, P.; Rossi, A.; Gridelli, C. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy. Expert Opin. Pharmacother. 2016, 17, 561–570. [Google Scholar] [CrossRef]
- Hartmann, J.T.; Lipp, H.-P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003, 4, 889–901. [Google Scholar] [CrossRef]
- Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of cisplatin nephrotoxicity. Toxins 2010, 2, 2490–2518. [Google Scholar] [CrossRef]
- Rana, M.A.; Khan, R.A.; Nasiruddin, M.; Khan, A.A. Amelioration of cisplatin-induced nephrotoxicity by ethanolic extract of Bauhinia purpurea: An in vivo study in rats. Saudi J. Kidney Dis. Transplant. 2016, 27, 41. [Google Scholar] [CrossRef]
- Basile, D.P.; Anderson, M.D.; Sutton, T.A. Pathophysiology of acute kidney injury. Compr Physiol. 2012, 2, 1303–1353, PMCID:3919808. [Google Scholar] [CrossRef] [PubMed]
- Abd El-Rhman, R.H.; El-Naga, R.N.; Gad, A.M.; Tadros, M.G.; Hassaneen, S.K. Dibenzazepine attenuates against cisplatin-induced nephrotoxicity in rats: Involvement of NOTCH pathway. Front. Pharmacol. 2020, 11, 567852. [Google Scholar] [CrossRef]
- Appenroth, D.; Fröb, S.; Kersten, L.; Splinter, F.-K.; Winnefeld, K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch. Toxicol. 1997, 71, 677–683. [Google Scholar] [CrossRef]
- Li, S.; Nagothu, K.; Ranganathan, G.; Ali, S.M.; Shank, B.; Gokden, N.; Ayyadevara, S.; Megyesi, J.; Olivecrona, G.; Chugh, S.S. Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury. Am. J. Physiol. Ren. Physiol. 2012, 303, F437–F448. [Google Scholar] [CrossRef]
- Eslamifar, Z.; Moridnia, A.; Sabbagh, S.; Ghaffaripour, R.; Jafaripour, L.; Behzadifard, M. Ameliorative effects of gallic acid on cisplatin-induced nephrotoxicity in rat variations of biochemistry, histopathology, and gene expression. BioMed. Res. Int. 2021, 2021, 2195238. [Google Scholar] [CrossRef]
- Ju, S.M.; Kang, J.G.; Bae, J.S.; Pae, H.O.; Lyu, Y.S.; Jeon, B.H. The flavonoid apigenin ameliorates cisplatin-induced nephrotoxicity through reduction of p53 activation and promotion of PI3K/Akt pathway in human renal proximal tubular epithelial cells. Evid.-based Complement. Altern. Med. 2015, 2015, 186436. [Google Scholar] [CrossRef]
- Volarevic, V.; Djokovic, B.; Jankovic, M.G.; Harrell, C.R.; Fellabaum, C.; Djonov, V.; Arsenijevic, N. Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J. Biomed. Sci. 2019, 26, 1–14. [Google Scholar] [CrossRef]
- Marullo, R.; Werner, E.; Degtyareva, N.; Moore, B.; Altavilla, G.; Ramalingam, S.S.; Doetsch, P.W. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE 2013, 8, e81162. [Google Scholar] [CrossRef]
- Yang, Y.; Liu, S.; Gao, H.; Wang, P.; Zhang, Y.; Zhang, A.; Jia, Z.; Huang, S. Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2. Free Radic. Biol. Med. 2020, 152, 821–837. [Google Scholar] [CrossRef]
- Hosohata, K. Role of oxidative stress in drug-induced kidney injury. Int. J. Mol. Sci. 2016, 17, 1826. [Google Scholar] [CrossRef]
- El-Beshbishy, H.A.; Bahashwan, S.A.; Aly, H.A.; Fakher, H.A. Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes. Eur. J. Pharmacol. 2011, 668, 278–284. [Google Scholar] [CrossRef]
- Ahmad, S. Platinum–DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers. 2010, 7, 543–566. [Google Scholar] [CrossRef]
- Manohar, S.; Leung, N. Cisplatin nephrotoxicity: A review of the literature. J. Nephrol. 2018, 31, 15–25. [Google Scholar] [CrossRef]
- Kawaida, K.; Matsumoto, K.; Shimazu, H.; Nakamura, T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc. Natl. Acad. Sci. USA 1994, 91, 4357–4361. [Google Scholar] [CrossRef]
- Yousef, M.I.; Hussien, H.M. Cisplatin-induced renal toxicity via tumor necrosis factor-α, interleukin 6, tumor suppressor P53, DNA damage, xanthine oxidase, histological changes, oxidative stress and nitric oxide in rats: Protective effect of ginseng. Food Chem. Toxicol. 2015, 78, 17–25. [Google Scholar] [CrossRef]
- Yarijani, Z.M.; Godini, A.; Madani, S.H.; Najafi, H. Reduction of cisplatin-induced renal and hepatic side effects in rat through antioxidative and anti-inflammatory properties of Malva sylvestris L. extract. Biomed. Pharmacother. 2018, 106, 1767–1774. [Google Scholar] [CrossRef]
- Oh, C.J.; Ha, C.-M.; Choi, Y.-K.; Park, S.; Choe, M.S.; Jeoung, N.H.; Huh, Y.H.; Kim, H.-J.; Kweon, H.-S.; Lee, J.-M. Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury. Kidney Int. 2017, 91, 880–895. [Google Scholar] [CrossRef]
- Divya, M.K.; Lincy, L.; Raghavamenon, A.C.; Babu, T.D. Ameliorative effect of Apodytes dimidiata on cisplatin-induced nephrotoxicity in Wistar rats. Pharm. Biol. 2016, 54, 2149–2157. [Google Scholar] [CrossRef]
- Pedraza-Chaverrí, J.; Barrera, D.; Maldonado, P.D.; Chirino, Y.I.; Macías-Ruvalcaba, N.A.; Medina-Campos, O.N.; Castro, L.; Salcedo, M.I.; Hernández-Pando, R. S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin. Pharmacol. 2004, 4, 1–13. [Google Scholar] [CrossRef]
- Romero, F.; Pérez, M.; Chávez, M.; Parra, G.; Durante, P. Effect of uric acid on gentamicin-induced nephrotoxicity in rats–role of matrix metalloproteinases 2 and 9. Basic Clin. Pharmacol. Toxicol. 2009, 105, 416–424. [Google Scholar] [CrossRef]
- Tena, N.; Martín, J.; Asuero, A.G. State of the art of anthocyanins: Antioxidant activity, sources, bioavailability, and therapeutic effect in human health. Antioxidants 2020, 9, 451. [Google Scholar] [CrossRef]
- Lin, B.W.; Gong, C.C.; Song, H.F.; Cui, Y.Y. Effects of anthocyanins on the prevention and treatment of cancer. Br. J. Pharmacol. 2017, 174, 1226–1243. [Google Scholar] [CrossRef]
- Azzini, E.; Giacometti, J.; Russo, G.L. Antiobesity effects of anthocyanins in preclinical and clinical studies. Oxid. Med. Cell. Longev. 2017, 2017, 2740364. [Google Scholar] [CrossRef]
- Sun, X.-H.; Zhou, T.-T.; Wei, C.-H.; Lan, W.-Q.; Zhao, Y.; Pan, Y.-J.; Wu, V.C. Antibacterial effect and mechanism of anthocyanin rich Chinese wild blueberry extract on various foodborne pathogens. Food Control 2018, 94, 155–161. [Google Scholar] [CrossRef]
- Zhang, J.; Wu, J.; Liu, F.; Tong, L.; Chen, Z.; Chen, J.; He, H.; Xu, R.; Ma, Y.; Huang, C. Neuroprotective effects of anthocyanins and its major component cyanidin-3-O-glucoside (C3G) in the central nervous system: An outlined review. Eur. J. Pharmacol. 2019, 858, 172500. [Google Scholar] [CrossRef]
- Reis, J.F.; Monteiro, V.V.S.; de Souza Gomes, R.; do Carmo, M.M.; da Costa, G.V.; Ribera, P.C.; Monteiro, M.C. Action mechanism and cardiovascular effect of anthocyanins: A systematic review of animal and human studies. J. Transl. Med. 2016, 14, 1–16. [Google Scholar] [CrossRef]
- Nomi, Y.; Iwasaki-Kurashige, K.; Matsumoto, H. Therapeutic effects of anthocyanins for vision and eye health. Molecules 2019, 24, 3311. [Google Scholar] [CrossRef]
- Alhoshani, A.R.; Hafez, M.M.; Husain, S.; Al-Sheikh, A.M.; Alotaibi, M.R.; Al Rejaie, S.S.; Alshammari, M.A.; Almutairi, M.M.; Al-Shabanah, O.A. Protective effect of rutin supplementation against cisplatin-induced Nephrotoxicity in rats. BMC Nephrol. 2017, 18, 194. [Google Scholar] [CrossRef]
- Sen, S.; Chakraborty, R.; Kalita, P. Dillenia indica fruit prevents cisplatin-induced kidney injury in experimental rats through modulation of oxidative stress, marker enzyme, and biochemical changes. Nutrire 2018, 43, 15. [Google Scholar] [CrossRef]
- Ellman, G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82, 70–77. [Google Scholar] [CrossRef]
- Aebi, H.; Wyss, S.R.; Scherz, B.; Skvaril, F. Heterogeneity of erythrocyte catalase II: Isolation and characterization of normal and variant erythrocyte catalase and their subunits. Eur. J. Mol. Biol. Biochem. 1974, 48, 137–145. [Google Scholar] [CrossRef]
- Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [Google Scholar] [CrossRef]
- Jiang, W.; Wen, D.; Cheng, Z.; Yang, Y.; Zheng, G.; Yin, F. Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-κB activation and inflammatory cytokines. J. Biochem. Mol. Toxicol. 2018, 32, e22220. [Google Scholar] [CrossRef]
- Güntürk, I.; Yazici, C.; Köse, S.K.; Dağli, F.; Yücel, B.; Yay, A.H. The effect of N-acetylcysteine on inflammation and oxidative stress in cisplatin-induced nephrotoxicity: A rat model. Turk. J. Med. Sci. 2019, 49, 1789–1799. [Google Scholar]
- Morsy, M.A.; Heeba, G.H. Nebivolol ameliorates cisplatin-induced nephrotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 2016, 118, 449–455. [Google Scholar] [CrossRef]
- Sharp, C.N.; Siskind, L.J. Developing better mouse models to study cisplatin-induced kidney injury. Am. J. Physiol. Ren. Physiol. 2017, 313, F835–F841. [Google Scholar] [CrossRef]
- Daugaard, G.; Abildgaard, U. Cisplatin nephrotoxicity: A review. Cancer Chemother. Pharmacol. 1989, 25, 1–9. [Google Scholar] [CrossRef]
- Awdishu, L.; Mehta, R.L. The 6R’s of drug induced nephrotoxicity. BMC Nephrol. 2017, 18, 1–12. [Google Scholar] [CrossRef]
- Herrera-Pérez, Z.; Gretz, N.; Dweep, H. A comprehensive review on the genetic regulation of cisplatin-induced nephrotoxicity. Curr. Genom. 2016, 17, 279–293. [Google Scholar] [CrossRef]
- Chakraborty, R.; Sen, S. Nephroprotective activity of Pisonia aculeata L. leaf extract against cisplatin induced nephrotoxicity and renal dysfunction in experimental rodents. Indian J. Exp. Biol. (IJEB) 2020, 58, 770–776. [Google Scholar]
- Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008, 73, 994–1007. [Google Scholar] [CrossRef]
- Peres, L.A.B.; Cunha Júnior, A.D.d. Acute nephrotoxicity of cisplatin: Molecular mechanisms. Braz. J. Nephrol. 2013, 35, 332–340. [Google Scholar] [CrossRef]
- Ridzuan, N.R.; Rashid, N.A.; Othman, F.; Budin, S.B.; Hussan, F.; Teoh, S.L. Protective role of natural products in cisplatin-induced nephrotoxicity. Mini-Rev. Med. 2019, 19, 1134–1143. [Google Scholar] [CrossRef]
- Kalra, P.; Karwasra, R.; Gupta, Y.K.; Ray, S.B.; Singh, S. Terminalia chebula supplementation attenuates cisplatin-induced nephrotoxicity in Wistar rats through modulation of apoptotic pathway. Nat. Prod. Res. 2019, 33, 1641–1645. [Google Scholar] [CrossRef]
- Gao, Z.; Liu, G.; Hu, Z.; Li, X.; Yang, X.; Jiang, B.; Li, X. Grape seed proanthocyanidin extract protects from cisplatin-induced nephrotoxicity by inhibiting endoplasmic reticulum stress-induced apoptosis. Mol. Med. Rep. 2014, 9, 801–807. [Google Scholar] [CrossRef]
- Ortega-Domínguez, B.; Aparicio-Trejo, O.E.; García-Arroyo, F.E.; León-Contreras, J.C.; Tapia, E.; Molina-Jijón, E.; Hernández-Pando, R.; Sánchez-Lozada, L.G.; Barrera-Oviedo, D.; Pedraza-Chaverri, J. Curcumin prevents cisplatin-induced renal alterations in mitochondrial bioenergetics and dynamic. Food Chem. Toxicol. 2017, 107, 373–385. [Google Scholar] [CrossRef]
- Saatkamp, C.J.; de Almeida, M.L.; Bispo, J.A.M.; Pinheiro, A.L.B.; Fernandes, A.B.; Silveira Jr, L. Quantifying creatinine and urea in human urine through Raman spectroscopy aiming at diagnosis of kidney disease. J. Biomed. Opt. 2016, 21, 037001. [Google Scholar] [CrossRef]
- Taal, M.; Brenner, B. Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int. 2006, 70, 1694–1705. [Google Scholar] [CrossRef]
- Thomas, R.; Kanso, A.; Sedor, J.R. Chronic kidney disease and its complications. Prim. Care Clin. Off. Pract. 2008, 35, 329–344. [Google Scholar] [CrossRef]
- Dabla, P.K. Renal function in diabetic nephropathy. World J. Diabetes. 2010, 1, 48. [Google Scholar] [CrossRef]
- Schnellmann, R.G. Toxic responses of the kidney. In Cassarett and Doull’s Toxicology. The Basic Science of Poisons, 7th ed.; McGraw-Hill Medical Publishing Division: New York, NY, USA, 2008; pp. 583–608. [Google Scholar]
- Sarnak, M.J.; Amann, K.; Bangalore, S.; Cavalcante, J.L.; Charytan, D.M.; Craig, J.C.; Gill, J.S.; Hlatky, M.A.; Jardine, A.G.; Landmesser, U. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019, 74, 1823–1838. [Google Scholar] [CrossRef]
- Ix, J.H.; Shlipak, M.G.; Liu, H.H.; Schiller, N.B.; Whooley, M.A. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: The heart and soul study. J. Am. Soc. Nephrol. 2003, 14, 3233–3238. [Google Scholar] [CrossRef]
- Rivadeneyra-Domínguez, E.; Becerra-Contreras, Y.; Vázquez-Luna, A.; Díaz-Sobac, R.; Rodríguez-Landa, J.F. Alterations of blood chemistry, hepatic and renal function, and blood cytometry in acrylamide-treated rats. Toxicol. Rep. 2018, 5, 1124–1128. [Google Scholar] [CrossRef]
- Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.L.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013, 382, 339–352. [Google Scholar] [CrossRef]
- Ridker, P.M.; MacFadyen, J.G.; Glynn, R.J.; Koenig, W.; Libby, P.; Everett, B.M.; Lefkowitz, M.; Thuren, T.; Cornel, J.H. Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 2018, 71, 2405–2414. [Google Scholar] [CrossRef]
- Zaki, N.; Alashwal, H.; Ibrahim, S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1133–1142. [Google Scholar] [CrossRef]
- Imai, E.; Matsuo, S.; Makino, H.; Watanabe, T.; Akizawa, T.; Nitta, K.; Iimuro, S.; Ohashi, Y.; Hishida, A. Chronic Kidney Disease Japan Cohort study: Baseline characteristics and factors associated with causative diseases and renal function. Clin. Exp. Nephrol. 2010, 14, 558–570. [Google Scholar] [CrossRef]
- Jayaganesh, R.; Pugalendhi, P.; Murali, R. Effect of citronellol on NF-kB inflammatory signaling molecules in chemical carcinogen-induced mammary cancer in the rat model. J. Biochem. Mol. Toxicol. 2020, 34, e22441. [Google Scholar] [CrossRef]
- Kumar, S.; Singh, B.; Singh, R. Catharanthus roseus (L.) G. Don: A review of its ethnobotany, phytochemistry, ethnopharmacology and toxicities. J. Ethnopharmacol. 2022, 284, 114647. [Google Scholar] [CrossRef]
- Adam, A.A.E.M. Isolation, Characterization and Biological Activity of Flavonoids from CordiaSinensis and Acacia Orefota; Sudan University of Science and Technology: Khartoum, Sudan, 2017; pp. 1–107. [Google Scholar]
- Putta, S.; Yarla, N.S.; Kumar, K.E.; Lakkappa, D.B.; Kamal, M.A.; Scotti, L.; Scotti, M.T.; Ashraf, G.M.; Rao, B.S.B.; Reddy, G.V. Preventive and therapeutic potentials of anthocyanins in diabetes and associated complications. Curr. Med. Chem. 2018, 25, 5347–5371. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Imam, F.; Kothiyal, P.; Alshehri, S.; Afzal, M.; Iqbal, M.; Khan, M.R.; Alanazi, A.A.H.; Anwer, M.K. Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level. Biomedicines 2023, 11, 804. https://doi.org/10.3390/biomedicines11030804
Imam F, Kothiyal P, Alshehri S, Afzal M, Iqbal M, Khan MR, Alanazi AAH, Anwer MK. Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level. Biomedicines. 2023; 11(3):804. https://doi.org/10.3390/biomedicines11030804
Chicago/Turabian StyleImam, Faisal, Preeti Kothiyal, Samiyah Alshehri, Muhammad Afzal, Muzaffar Iqbal, Mohammad Rashid Khan, Abdulrazaq Ahmed Hattab Alanazi, and Md. Khalid Anwer. 2023. "Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level" Biomedicines 11, no. 3: 804. https://doi.org/10.3390/biomedicines11030804
APA StyleImam, F., Kothiyal, P., Alshehri, S., Afzal, M., Iqbal, M., Khan, M. R., Alanazi, A. A. H., & Anwer, M. K. (2023). Hirsutidin Prevents Cisplatin-Evoked Renal Toxicity by Reducing Oxidative Stress/Inflammation and Restoring the Endogenous Enzymatic and Non-Enzymatic Level. Biomedicines, 11(3), 804. https://doi.org/10.3390/biomedicines11030804